Wang Chen (far right), vice president of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences, speaking at a conference in Wuhan on Feb. 5, 020. The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus are to start taking the drug on Thursday (Fen 6). - Xinhua
BEIJING (Xinhua): The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday (Feb 6), according to an official conference on Wednesday.
The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
